102 related articles for article (PubMed ID: 28244758)
1. Glycosylation Changes in Serum Proteins Identify Patients with Pancreatic Cancer.
Drabik A; Bodzon-Kulakowska A; Suder P; Silberring J; Kulig J; Sierzega M
J Proteome Res; 2017 Apr; 16(4):1436-1444. PubMed ID: 28244758
[TBL] [Abstract][Full Text] [Related]
2. Isomer-specific profiling of N-glycans derived from human serum for potential biomarker discovery in pancreatic cancer.
Liu Y; Wang C; Wang R; Wu Y; Zhang L; Liu BF; Cheng L; Liu X
J Proteomics; 2018 Jun; 181():160-169. PubMed ID: 29674015
[TBL] [Abstract][Full Text] [Related]
3. Identification of the epitope of 10-7G glycan antibody to recognize cancer-associated haptoglobin.
Morishita K; Maki Y; Takamatsu S; Ito N; Koda S; Motooka K; Kamada Y; Kajihara Y; Miyoshi E
Anal Biochem; 2020 Mar; 593():113588. PubMed ID: 31981485
[TBL] [Abstract][Full Text] [Related]
4. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
[TBL] [Abstract][Full Text] [Related]
5. Glycoproteins and glycoproteomics in pancreatic cancer.
Pan S; Brentnall TA; Chen R
World J Gastroenterol; 2016 Nov; 22(42):9288-9299. PubMed ID: 27895417
[TBL] [Abstract][Full Text] [Related]
6. Solvent interaction analysis as a proteomic approach to structure-based biomarker discovery and clinical diagnostics.
Zaslavsky BY; Uversky VN; Chait A
Expert Rev Proteomics; 2016; 13(1):9-17. PubMed ID: 26558960
[TBL] [Abstract][Full Text] [Related]
7. Cancer serum biomarkers based on aberrant post-translational modifications of glycoproteins: Clinical value and discovery strategies.
Silva ML
Biochim Biophys Acta; 2015 Dec; 1856(2):165-77. PubMed ID: 26232626
[TBL] [Abstract][Full Text] [Related]
8. Glycosylation of serum haptoglobin as a marker of gastric cancer: an overview for clinicians.
Jeong S; Oh MJ; Kim U; Lee J; Kim JH; An HJ
Expert Rev Proteomics; 2020 Feb; 17(2):109-117. PubMed ID: 32149536
[No Abstract] [Full Text] [Related]
9. Cancer glycan epitopes: biosynthesis, structure and function.
Pearce OMT
Glycobiology; 2018 Sep; 28(9):670-696. PubMed ID: 29546349
[TBL] [Abstract][Full Text] [Related]
10. Insights on N-glycosylation of human haptoglobin and its association with cancers.
Zhang S; Shang S; Li W; Qin X; Liu Y
Glycobiology; 2016 Jul; 26(7):684-692. PubMed ID: 26873173
[TBL] [Abstract][Full Text] [Related]
11. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers.
Nakano M; Nakagawa T; Ito T; Kitada T; Hijioka T; Kasahara A; Tajiri M; Wada Y; Taniguchi N; Miyoshi E
Int J Cancer; 2008 May; 122(10):2301-9. PubMed ID: 18214858
[TBL] [Abstract][Full Text] [Related]
12. Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis.
Morishita K; Ito N; Koda S; Maeda M; Nakayama K; Yoshida K; Takamatsu S; Yamada M; Eguchi H; Kamada Y; Miyoshi E
Clin Chim Acta; 2018 Dec; 487():84-89. PubMed ID: 30189188
[TBL] [Abstract][Full Text] [Related]
13. Proteomic and genomic profiling of pancreatic cancer.
Ansari D; Torén W; Zhou Q; Hu D; Andersson R
Cell Biol Toxicol; 2019 Aug; 35(4):333-343. PubMed ID: 30771135
[TBL] [Abstract][Full Text] [Related]
14. Aberrant glycosylation as biomarker for cancer: focus on CD43.
Tuccillo FM; de Laurentiis A; Palmieri C; Fiume G; Bonelli P; Borrelli A; Tassone P; Scala I; Buonaguro FM; Quinto I; Scala G
Biomed Res Int; 2014; 2014():742831. PubMed ID: 24689054
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
[TBL] [Abstract][Full Text] [Related]
16. Label-free glycopeptide quantification for biomarker discovery in human sera.
Mayampurath A; Song E; Mathur A; Yu CY; Hammoud Z; Mechref Y; Tang H
J Proteome Res; 2014 Nov; 13(11):4821-32. PubMed ID: 24946017
[TBL] [Abstract][Full Text] [Related]
17. Proteomic profiling of pancreatic cancer for biomarker discovery.
Chen R; Pan S; Brentnall TA; Aebersold R
Mol Cell Proteomics; 2005 Apr; 4(4):523-33. PubMed ID: 15684406
[TBL] [Abstract][Full Text] [Related]
18. Glycans as cancer biomarkers.
Adamczyk B; Tharmalingam T; Rudd PM
Biochim Biophys Acta; 2012 Sep; 1820(9):1347-53. PubMed ID: 22178561
[TBL] [Abstract][Full Text] [Related]
19. Current proteomic analysis and post-translational modifications of biomarkers in human lung cancer materials.
Sinchaikul S; Hongsachart P; Sriyam S; Tantipaiboonwong P; Phutrakul S; Chen ST
Chang Gung Med J; 2008; 31(5):417-30. PubMed ID: 19097588
[TBL] [Abstract][Full Text] [Related]
20. Glycomic profiling of targeted serum haptoglobin for gastric cancer using nano LC/MS and LC/MS/MS.
Lee SH; Jeong S; Lee J; Yeo IS; Oh MJ; Kim U; Kim S; Kim SH; Park SY; Kim JH; Park SH; Kim JH; An HJ
Mol Biosyst; 2016 Nov; 12(12):3611-3621. PubMed ID: 27722599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
